NAD+

What it is

NAD+ is about as fundamental as biology gets. It’s a coenzyme — a helper molecule — present in every living cell, the currency your mitochondria use to turn food into ATP (cellular energy), and the fuel for a family of repair-and-longevity enzymes called sirtuins. And it genuinely declines with age: that part is well-documented and not in dispute. The whole premise of NAD+ supplementation is straightforward — if the molecule falls with age and powers your energy and repair machinery, topping it back up is worth pursuing.

There are two ways people do that, and they’re worth understanding as two different tools rather than as one being “real” and the other not:

• Oral precursors (NR and NMN) — you can’t usefully swallow NAD+ itself (too big and unstable to absorb intact), so oral protocols use precursors your cells convert into NAD+. This route has the deepest human trial base.
• IV / injectable NAD+ — delivering NAD+ directly, the form used in the booming NAD+ IV-clinic world and sold as injectable by vendors like Alyve. This route has strong real-world adoption and user-reported energy/clarity benefits, with formal efficacy trials still being built out.

Both are legitimate ways to engage NAD+ biology. This article lays out what each one delivers.

The simplest way to think about it (NEW 2026-06-12, via Dr. Ashley Froese, primary care MD): “NAD is like a battery charger for your cells. Using NAD is like charging the battery on your phone. Peptides, depending on which one you’re going for, are kind of like upgrading the operating system. I know that updating the system sounds more appealing up front, but you kind of need your battery charged, so it can be a little tricky to decide what you need. And hey, if you can do both, why not?” That framing puts NAD on the foundational layer — you restore the cellular energy first, then you add the peptide signaling on top. It matches the clinical-sequencing logic in this article (acute-deficit recovery → maintenance) but in layman’s terms a non-clinician will actually remember. The boost from a single NAD pulse lasts days, not forever — “just like unplugging your phone doesn’t allow the battery to stay charged forever” — which is why the protocols below are dosed, not one-shot. Source:.

How it works

NAD+ does two big jobs. First, redox: it shuttles electrons in and out of the energy-production line, flipping between NAD+ and NADH so your mitochondria can make ATP. Second, signaling: NAD+ is the substrate (the raw material that gets consumed) for three enzyme families — sirtuins (deacetylases tied to longevity and gene regulation), PARPs (DNA-repair enzymes), and CD38 (an immune/aging enzyme that consumes NAD+ and rises with age — in a mouse aging model, CD38 knockout mice maintained NAD+ levels at every age while wild-type mice showed progressive decline, confirming CD38 as the dominant NAD±consuming driver of age-related depletion).

Because CD38 and PARPs chew through NAD+ faster with age and inflammation, NAD+ levels fall — and restoring it aims to support sirtuin activity, DNA repair, and mitochondrial function.

The route matters mechanistically: oral NR/NMN raise NAD+ by feeding the cell’s own conversion pathway, while IV/injectable NAD+ delivers the molecule directly. That’s why the two have separate evidence stories — and why it’s worth seeing both clearly.

What the research shows

** Oral NR / NMN: a deep human trial base.** This is one of the better-studied longevity interventions — the 0019 corpus alone holds 50 randomized controlled trials plus 7 meta-analyses across the NR/NMN precursor field, making this by far the most trial-backed compound in the catalog. The highlights:

• NR reliably raises blood NAD+ dose-dependently: +22%, +51%, +142% at 100/300/1000 mg. The biochemical effect is rock-solid and reproducible.
• NMN 250 mg/day improved muscle insulin sensitivity in prediabetic postmenopausal women — a standout positive functional result.
• NR improved 6-minute walk distance (+17.6 m) in peripheral artery disease.
• NR reduced airway inflammation (sputum IL-8 ~−53%) in COPD.
• A pharmaceutical-grade NMN (MIB-626) safely raised blood NAD+ in a hospitalized RCT, adding controlled safety data on the NMN side.

Where functional results are population-specific: NR raised brain NAD+ 2.6× but didn’t move cognition in mild cognitive impairment; it raised the muscle NAD+ metabolome without changing bioenergetics in healthy aged men. The honest synthesis from a 2023 review of 25 NR studies: oral NR dependably restores NAD+, while clinically dramatic functional effects show up in specific populations (metabolic, vascular, inflammatory) more than in already-healthy people. One practical dosing note from the literature: very high NMN (~2 g/day) was associated with reduced thigh muscle mass — so more is not better; the studied sweet spot is moderate.

The precursor hierarchy: which form, and why (Anderson). A useful clinical frame ranks the oral options by how many conversion steps they sit from NAD+:

• NR (nicotinamide riboside) — fewest steps, fastest-acting oral form; the “energy now” choice.
• NMN — a few steps further; the form with the strongest single positive functional RCT (Yoshino).
• Niacinamide — one step closer to NAD+ than niacin, non-flushing, and the cheapest; the preferred long-term maintenance form.
• Niacin — most steps, and it causes flushing; usable but the least comfortable.
• IV NAD+ / IV NR — direct, fastest, most expensive; for severe deficit states.

That maps onto a clinical-sequencing protocol: Stage 1 (acute/severe: long COVID, chronic fatigue, post-surgery) leans on IV NAD+ or IV NR plus an oral NR backup; Stage 2 transitions as energy returns; Stage 3 settles into oral niacinamide for cheap long-term maintenance — “match the supplement to the level of pathology”. Two roles of NAD+ that get overlooked in the longevity framing are worth knowing: it’s a cofactor in neurotransmitter synthesis and in histamine clearance (a final clearance step uses B1 + B3), which is why NAD+ sometimes appears in histamine-intolerance/MCAS protocols [ESTABLISHED enzymology / ANEC, Anderson].

/ IV / injectable NAD+: clinic-popular, user-reported. The IV/injectable route is where adoption has exploded — NAD+ drips and injections are a mainstay of wellness and longevity clinics, with users widely reporting improved energy, mental clarity, and recovery. Formal controlled efficacy trials for the IV route are still being run, so today’s evidence is real-world and tolerability-focused: a tolerability pilot found IV NAD+ recipients commonly experienced infusion-related sensations — GI symptoms, increased heart rate, chest pressure — which is why slow infusion is standard and why injectable/IM dosing is often preferred for comfort. The large body of clinic and user reports is tier, but it’s substantial and consistent, and it’s the reason the category keeps growing. For someone interested in NAD+, the IV/injectable route is the high-dose, fast-delivery option; the oral route is the trial-backed daily option. Both are valid choices.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Oral precursors (the RCT-backed route):

• NR: 300–1000 mg/day; well tolerated, raises NAD+ within ~2 weeks.
• NMN: 250–500 mg/day is the common, evidence-aligned range (the positive insulin study used 250 mg). Keep below the ~2 g/day range where the reduced-muscle-mass signal appeared.
• Take with food, in the morning, to avoid any sleep disruption.

Injectable / IV NAD+ (Alyve’s form):

• IV clinics commonly run 500–1000 mg over 1–2 hours; intramuscular (IM) injections run 50–250 mg. Slower delivery = more comfort.
• Reconstitution math (objective): a 500 mg vial in 5 ml bacteriostatic water = 100 mg/ml. So a 50 mg dose = 0.5 ml; a 100 mg dose = 1 ml. Adjust water volume to the dose precision you want.

The complete SubQ protocol (NEW 2026-06-13, via Dr. John, med-spa practitioner-trainer:). Dr. John walks med-spa nurses through a full Phase-1/2/3 SubQ schema; it’s the most detailed SubQ NAD+ protocol in the KB and is reproduced here as the practitioner-side reference. Cross-reference Jones DC and Anderson for convergence on the SubQ-as-sweet-spot framing.

Phase	Weeks	Dose	Frequency	Purpose
1: Initiation (loading)	1-2	25 mg	twice/week (Mon + Wed/Thu)	Start low, assess tolerance
	3-4	50 mg	twice/week	Double from week 2
	5-8	100 mg	twice/week	Loading-phase ceiling
2: Maintenance	after ~2-month load	~100 mg	weekly, every-other-week, or monthly	Steady-state maintenance
3: Cycle	3 months ON, 1 month OFF	(off)	(off)	Endogenous-NAD recovery
Re-initiation	after the off month	50 mg → 100 mg	twice/week → weekly	Modified ramp, not full Phase-1 repeat

Why ramp slowly through the load: “If you go really high dose right at the beginning, you’re going to get a lot of those side effects [the IV-style intense reaction].” Starting at 25 mg twice weekly and stepping up over ~8 weeks avoids the IV-style acute response while building steady-state.

Why cycle 3-on / 1-off: Dr. John’s clinician-protocol rationale is that “your body’s going to get used to not having to worry about NAD and it’s going to stop producing its own NAD because you got plenty of it… You don’t want to completely replace their native NAD.” This claim — that chronic exogenous NAD+ feedback-suppresses endogenous biosynthesis — is mechanistically plausible (product-inhibition of NAMPT/NMNAT is general endocrine logic) but is not directly cited to a study in the source and is against primary literature. Treat the cycling protocol as defensible clinician folk-wisdom for now; do not propagate the underlying mechanism claim into customer-facing content as established. Source:.

Critical terminology disambiguation: Dr. John’s source uses “bi-weekly” inconsistently: at the loading phase it means twice per week (Mondays + Wednesdays/Thursdays); at the maintenance phase it appears to mean every other week. The table above writes the frequency explicitly to avoid the source-ambiguity. Never write “bi-weekly” in OHM derivative content: always disambiguate.

Injection mechanics (clean clinician technique reference,): 29-31 gauge insulin needle, 6-8 mm length, SubQ only (not IM). Sites: abdomen (at least 2 inches from navel), thigh, back of arm — any area with adequate subcutaneous fat. Rotate sites within and across body regions.

The three delivery routes, compared (Jones DC). A practical cost/speed map:

• Oral NMN/NR — 250–500 mg/day, roughly $60–90/mo, effect in 2–3 weeks. Cheapest, slowest.
• Subcutaneous NAD+ — roughly $150–250/mo, effect in days-to-weeks. Jones’s preferred “sweet spot,” and the route Alyve’s injectable product serves: more potent and faster than oral, far cheaper and more convenient than clinic IV.
• IV NAD+ — 500–1,000 mg per session at $500–1,000/session, same-day effect. Highest delivered dose, most expensive, requires a clinic.

The 8–12 week plateau, and the TMG fix. A common real-world pattern: NAD+ benefits plateau after 8–12 weeks if you don’t cycle or add a methyl-donor cofactor. NAD+ metabolism consumes methyl groups, so adding TMG (trimethylglycine) helps the body keep producing NAD+ efficiently. This is the supply-side complement to the “prevent the loss” approach (NNMT inhibition, below).

The salvage-pathway caveat (advanced: and a real safety note). NAD+ runs on a recycling loop (the salvage pathway). Two “leaks” drain it: the NNMT enzyme and CD38, both of which siphon off nicotinamide before it can be recycled. Some advanced longevity stacks add an NNMT inhibitor (e.g. 5-Amino-1MQ — not an Alyve SKU) to plug one leak. The caveat worth surfacing: if you inhibit NNMT but don’t supply enough NAD+ substrate and CD38 is high, NAD+ can reportedly get shunted toward fueling senescent and cancer cells — so NNMT inhibition should never run standalone; it pairs with NAD+ precursor supply and a CD38 strategy. For most people, the simpler NAD+ (oral or subQ) ± TMG route is plenty.

Why NAD+ falls with age: the “drain” problem, and what to address upstream (added 2026-07-18). The precursor conversation mostly focuses on supply — add more NMN, NR, or injectable NAD+ to top the pool back up. That framing is valid, but it addresses only one side of the equation. Mouse knockout research confirms the age-related NAD+ decline is primarily a consumption problem: the body isn’t producing less, something is burning through it faster. Two specific mechanisms drive the consumption side:

(1) Senescent cells → CD38 over-activation. Cells that accumulate damage and enter a senescent (non-dividing, stuck) state release inflammatory signals — the senescence-associated secretory phenotype (SASP) — that ramp up CD38 activity. CD38 uses NAD+ as fuel to produce the immune signaling molecules that respond to that inflammatory load. More senescent cells → more SASP → more CD38 activity → more NAD+ consumed. The mouse knockout data cited above (PMID 27304511) quantifies this as the dominant aging mechanism: eliminating CD38 was sufficient to maintain NAD+ at youthful levels regardless of age.

(2) Damaged mitochondria → chronic PARP activation. Mitochondria generating excess reactive oxygen species from structural damage create downstream DNA strand breaks and oxidative hits to nuclear material. PARPs are the first-responder DNA-repair enzymes — and they consume NAD+. When mitochondrial damage is persistent and unresolved, PARPs run chronically, creating a second independent NAD+ drain that runs in parallel with CD38. SS-31 (Elamipretide)'s cardiolipin-stabilization mechanism directly addresses this drain: by stabilizing the inner mitochondrial membrane, SS-31 reduces electron leak → less ROS → less structural DNA damage → reduced chronic PARP activation ``.

Three upstream levers that reduce consumption (complement to precursor supply):

• Exercise — increases NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway. Human intervention data: skeletal muscle NAMPT protein increased ~127% after 3 weeks of training in sedentary subjects; aerobic and resistance exercise both reverse age-dependent NAMPT decline. This is the most accessible upstream lever — available to everyone, free.
• SS-31 (Elamipretide) — reduces mitochondrial structural damage (cardiolipin stabilization → less ROS) and therefore the PARP-driven NAD+ drain. See SS-31 (Elamipretide) for full protocol; 50+ indication is the threshold where mitochondrial dysfunction is meaningful.
• Fisetin (a senolytic flavonoid — not a peptide, not an Alyve SKU at this time) — clears senescent cells, reducing the SASP-driven CD38 over-activation at the root of Drain 1. Pre-clinical data: fisetin was the most potent senolytic among 10 flavonoids tested, reducing senescent cell burden and SASP markers in aged mice. Note: “Fisetin DRI” is a commercial branding term — no distinct scientific literature behind it; the documented molecule is plain fisetin (CAS 528-48-3). No OHM affiliate product currently [FUTURE-MONETIZATION].

The precursor (supply) and upstream-drain-reduction (exercise + SS-31 + fisetin) strategies are complementary. The most complete NAD+ protocol works both sides of the equation. For most people starting out: supply first (oral NR/NMN or SubQ NAD+) + consistent exercise; add SS-31 at 50+ or with lab-confirmed mitochondrial dysfunction; consider fisetin when the senolytic layer becomes relevant.

Where experts differ. The cleanest divide is oral vs. injectable: the oral camp points to the human RCT base and daily convenience; the IV/injectable camp points to higher achievable doses, faster onset, and a large body of user-reported energy and clarity benefits — and the subcutaneous route splits the difference as the cost/potency sweet spot. Many people use both — oral NR/NMN daily as a baseline, periodic subQ/IV NAD+ for a stronger pulse. Within injectable use, lower-and-slower (IM/subQ, split doses) is the comfort-maximizing convention.

Stacking. NAD+ sits in the mitochondrial/longevity lane alongside MOTS-c (the two arms of mitochondrial support — NAD+ supplies the sirtuin substrate, MOTS-c drives the AMPK/SIRT1-PGC1-α machinery). It’s commonly paired with sirtuin-activating compounds and broader longevity stacks, and the most complete NAD+ approach combines supply (precursors), cofactor cycling (TMG), and prevent-the-loss (NNMT inhibition).

The Retatrutide + MOTS-c + NAD+ 3-stack (DeMesquita, 2026): NAD+'s role in this specific stack is the oxidative-stress buffer for the cellular ramping that MOTS-c drives. The logic: Retatrutide creates a caloric deficit (the high-stress state); MOTS-c amplifies metabolic efficiency under that deficit; the increased throughput generates more reactive oxygen species as a side effect; NAD+ supplies the substrate for the antioxidant + DNA-repair systems (SIRT1, PARP) that handle the oxidative load. This is a mechanism-plausible practitioner synthesis (the premises are each individually well-established; the direct integration as a clinical-stack protection rationale is, not trial-derived). The stack is distinct from Jones’s Three-Hands-of-Aging stack (Reta + GHK-Cu + MOTS-c) which uses GHK-Cu for gene-expression layering rather than NAD+ for oxidative-stress buffering — both are defensible, and per MOTS-c §Stacking, practitioners have at least three protective-layer options when running MOTS-c: SS-31 (hardware repair), NAD+ (oxidative-stress buffer + DNA-repair substrate), or GHK-Cu (gene-expression layer).

Coadministration tip: combine NAD+ with your peptide injection in the same syringe to reduce injection count. Common practitioner pattern for a Reta + MOTS-c + NAD+ stack:

• Monday: 50 mg NAD+ + 1 mg Retatrutide (combined in one syringe)
• Wednesday: 50 mg NAD+ + 500 mcg–1 mg MOTS-c pre-training (combined)
• Friday: 50 mg NAD+ + 500 mcg–1 mg MOTS-c pre-training (combined)

Important stability caveat: in-syringe coadministration of NAD+ with peptides is practitioner convention, not formally trialed for stability. NAD+ reconstituted in bacteriostatic water is mildly acidic (pH ~3), and prolonged contact with peptides at that pH could theoretically affect peptide stability. The practical guidance: draw + inject within minutes of combining, don’t pre-mix and store. At the minutes-scale window of a fresh draw + immediate injection, the coadministration is widely practiced and generally tolerated. If you want to be more conservative — or if you notice reduced effect after combining — use separate syringes; the convenience benefit is real but the stability data is not formal. Sodium-bicarbonate-buffered NAD+ formulations (less acidic, available from some compounding pharmacies) reduce the pH risk more directly than the draw-and-go workaround does.

The “burnt-out user shouldn’t press on the gas” caveat (added 2026-06-24). NAD+ increases energy production AND the demand for that energy as the system spools up. For users who arrive at the conversation with HPA-axis dysregulation, cortisol dysregulation, adrenal fatigue, or genuine chronic-stress burnout, NAD+ can paradoxically make things worse — the body needs structural support, not more gas pedal. The functional-medicine alternative for this profile is methylene blue, which streamlines the existing electron-transport chain (improves efficiency without adding new metabolic demand) rather than pushing harder on a system that’s already overworked… MOTS-c vs NAD+ vs methylene blue — the decision tree lives in MOTS-c under “match the tool to the symptom presentation”; check it before stacking these.

Side effects & management

Oral NR/NMN: broadly well tolerated in RCTs — no niacin-style flushing, no LDL elevation at standard doses. Occasional mild nausea on an empty stomach or headache at higher doses; take with food. Keep NMN out of the ~2 g/day range given the muscle-mass signal. One pattern to expect when starting precursors too high or too fast: an over-caffeinated, jittery feeling — racing heart, sweating, disrupted sleep — which is sudden mitochondrial activation, not danger. The fix is the same as everywhere here: start low, work up, dose in the morning. Niacin (not niacinamide) additionally causes a harmless flush; niacinamide avoids it.

IV/injectable NAD+: the main reported effects are infusion-related sensations — chest pressure, a racing heart, flushing, GI distress, leg heaviness — which come on during fast administration and resolve when delivery slows or stops. A practitioner-side clinical description of the IV NAD+ acute response: “chest tightness, the anxiety, the nausea, that feeling of impending doom”. The pilot logged no serious adverse events. The entirely practical management lever is speed: slow the infusion or split IM doses and the sensations largely disappear, which is exactly what experienced clinics do. As with any injectable, verified sterility and purity matter — which is where a COA’d product earns its place.

SubQ-specific side effect: local injection-site reaction (NEW 2026-06-13). The main SubQ side effect is a mosquito-bite-style local welt — red, itchy, small, resolves in 1-2 hours. Mechanism per Dr. John: “NAD is naturally acidic, so it’s a bit irritating to the tissue. It’s not an allergy. It’s just a normal response.”. Pre-emptively tell the patient: “after the shot, it’s normal to get a small red itchy welt at the injection site for an hour or two — it’s not an allergy, it’s the NAD+ pH.” Compared to the IV’s systemic acute response, the SubQ profile is far easier to tolerate because “the absorption is so slow and controlled”.

An important clarification on what NAD+ welt is NOT. NAD+ is not a peptide — it’s a dinucleotide cofactor (nicotinamide adenine dinucleotide). So the welt is NOT the MRGPRX2 / cationic-peptide-driven mast-cell degranulation mechanism that explains GHK-Cu and MOTS-c injection-site reactions (see GHK-Cu / MOTS-c for that mechanism). The NAD+ welt mechanism is acidic-pH + tissue irritation, a different biology. But the practical mitigations are the same because they all reduce local concentration / dispersion rate of any irritant:

1. Dilute the reconstituted NAD+ with extra bacteriostatic water → lower per-volume concentration.
2. Inject slowly → not delivering a concentrated acidic bolus to one spot.
3. Warm the solution to room temperature before injecting → disperses more evenly through tissue.
4. For severe cases, pre-medicate with an H1 antihistamine — historically less effective for NAD+ welts than for cationic-peptide welts (because the mechanism isn’t histamine-driven) but reasonable to try if the other three steps aren’t enough. Sodium-bicarbonate-buffered NAD+ formulations (if available from the compounding pharmacy) reduce the acidic-pH driver more directly than antihistamines do.

When the NAD+ reaction IS NOT just local — see a doctor. Same hard line as everywhere in this KB: stop the protocol and seek medical attention if you see redness/swelling spreading well beyond the injection site, difficulty breathing, a rash moving across the body, or swelling in the face or throat. Source:.

Hard contraindications: the two NO-GO patient classes (NEW 2026-06-13, via Dr. John clinician-protocol rule):

• Active cancer: hard NO. The cancer-cell-metabolism logic: cancer cells preferentially use glycolysis and have elevated NAD+ turnover; supplementing the substrate is theoretically a risk for fueling tumor metabolism. Cross-link to the existing senescent-cell/cancer-cell ALT-activation concern flagged in the Williams/Alex NNMT-cycling section above — the underlying biology converges on “high NAD+ in the presence of high CD38 or active malignancy is not what you want.”
• Pregnancy + breastfeeding: hard NO. No safety data, period. “Grow the baby, feed the baby, and then we can work on ourselves again.”

These are flat-rule contraindications across the NAD+ category (oral, SubQ, IV) — not specific to one route.

Regulatory status

NR holds GRAS status and is sold as a dietary supplement. NMN sits in regulatory limbo: the FDA excluded it from the dietary-supplement category in 2022 after a drug company filed it as an investigational drug, so its legal status is contested. IV/injectable NAD+ is not an FDA-approved therapy; it’s used widely in wellness, longevity, and compounding settings. Alyve sells its NAD+ research-use-only (“not for human consumption”). These are the regulatory facts; the IV-clinic category operates in the wellness/compounding space and continues to grow.

The Alyve product

• Product: NAD+ — $79 (500 mg, IN STOCK) / $110 (1000 mg, out of stock). This is the injectable form.
• COA: 99.49% purity, lot NAD165, identity confirmed by Freedom Diagnostics Testing (independent 3rd party; HPLC-UV purity + LC-MS identity). A nice transparency detail: the 500 mg-labeled vial assayed at 509 mg of active — you’re getting slightly more than the label, at genuinely high purity.
• Specs: CAS 53-84-9; C21H27N7O14P2; MW 663.43 g/mol; coenzyme (dinucleotide); hygroscopic, light-sensitive — keep desiccated, reconstitute fresh, protect from light, use within ~7 days.
• Alyve’s copy describes it as “research-grade nicotinamide adenine dinucleotide for cellular metabolism and sirtuin activation studies.”

The trust angle: injectable NAD+ from gray-market sources carries real sterility and purity risk. Alyve’s 99.49% third-party COA with confirmed identity and slightly-over-label content is the verified-clean tier — for an injectable, that verification is the whole point.

CTA: Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail.

Technical & analytical reference (chemistry & QC)

Molecular identity verified against PubChem (2026-06-23). NAD⁺ is a coenzyme/dinucleotide, not a peptide — it’s two ribonucleotides (nicotinamide and adenine) joined by a pyrophosphate bridge. Covered here because it’s the dominant longevity adjunct stacked with mitochondrial peptides (MOTS-c, SS-31 (Elamipretide)) and because the precursor space (NMN, NR, NAD⁺ itself) is the source of significant consumer confusion.

Field	Value
Molecular formula	C₂₁H₂₇N₇O₁₄P₂ (PubChem CID 5892)
Average MW	663.43 g/mol
CAS	53-84-9 (free acid, anhydrous); hydrate forms have separate CAS numbers
Class	Pyridine dinucleotide coenzyme; the oxidized form of the NAD⁺/NADH redox pair
SMILES	C1=CC(=C[N+](=C1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N
Identity / purity	HPLC at A₂₆₀ (ε ≈ 18,000 M⁻¹·cm⁻¹) is the standard assay; ≥98% purity; ADP-ribose and free nicotinamide are the typical degradation impurities to monitor
Storage / preparation	Powder −20 °C, desiccated, light-protected; solutions are pH-stability-asymmetric — NAD⁺ degrades in alkaline pH; NADH degrades in acidic pH — prepare fresh in cold buffer near neutral pH. SubQ injectable solutions for clinic / take-home use are typically formulated at pH 6-7
Counterion	Often supplied as the disodium salt for solubility (CAS 20111-18-6)
Degradation / stability	NAD⁺ → nicotinamide + ADP-ribose under alkaline conditions; NADH → ADP-ribose + dihydronicotinamide under acidic. Heat-labile (do NOT autoclave). The IV-clinic formulation question is sterile filtration (0.22 μm), not heat sterilization
Related precursors	NMN (nicotinamide mononucleotide, PubChem CID 14180, MW 334.22, CAS 1094-61-7); NR (nicotinamide riboside, PubChem CID 439924, MW 255.25, CAS 1341-23-7) — different upstream entry points to the same NAD salvage pathway

Verification reference: PubChem CID 5892. The clinical / consumer-facing variability is delivery (oral NMN/NR vs. SubQ NAD⁺ vs. IV NAD⁺) and dose, not molecular identity — all three roads enter the NAD⁺ pool the same way once absorbed.

Sources

1. : 31278280 — Conze 2019, NR dose-response NAD+ elevation
2. : 33888596 — Yoshino 2021, NMN improves insulin sensitivity
3. : 38871717 — McDermott 2024, NR in PAD
4. : 39548320 — Norheim 2024, NR reduces airway inflammation (COPD)
5. : 37994989 — Orr 2024, NR in MCI
6. : 31412242 — Elhassan 2019, NR muscle NAD+ metabolome
7. : 37478182 — Damgaard & Treebak 2023, systematic review of oral NR
8. : 24786309 — Imai & Guarente 2014, NAD+/sirtuins review
9. : 26785480 — Verdin 2015, NAD+ in aging review
10. IV NAD+ tolerability pilot, Frontiers in Aging (2026) — https://pmc.ncbi.nlm.nih.gov/articles/PMC12907335/
11. : 40746868 — Pencina 2025, MIB-626 (NMN) safely raises NAD+ RCT (FASEB Bioadv)
12. Healthspan Research (2025) — NAD+ booster review (high-NMN/muscle-mass finding) — https://www.gethealthspan.com/research/article/nad-boosters
13. : 35388296 — Yang 2022, whole-blood NAD+ declines with age (n=1518) — human age-decline anchor (via thepeptidelist.com)
14. (4-form precursor hierarchy + clinical sequencing + jitter side-effects + histamine/neurotransmitter roles); (3-route cost comparison + subQ sweet-spot + TMG plateau fix); (NAD salvage-pathway / NNMT-CD38 leaks + senescent-cell/cancer caveat)
15. (this synthesis pass) ·
16. Alyve product page — https://alyvepeptides.com/product/nad/ · (0019 corpus, 2,659 records / 50 RCTs / 7 meta-analyses) · ·
17. (added 2026-06-12) — Dr. Ashley Froese (primary care MD, “This Is Not Covered” channel, Mesa AZ direct primary care clinic). 6:55 beginner-audience NAD-vs-peptides decision-framework explainer. Source for the battery-vs-OS-upgrade analogy (callout in “What it is” above) and the “you have to do the work / they’re not magic” caveat (Content hook #6 above). Also surfaces the wellness-spa-markup callout from an MD-on-the-record (“There’s no reason for them to mark up peptide packages to thousands of dollars when they’re selling you things that you can just get online”): usable in OHM positioning content with attribution.Do NOT propagate her oversimplified “NAD prevents dementia” framing ( mouse-memory mentions, no PMIDs cited — existing wiki Orr 2024 PMID 37994989 shows NR raised brain NAD+ 2.6× but did NOT move cognition in MCI; wiki’s existing honest framing is the correct one). Cost figures she states (NAD IV $200-500/session, NMN $30-60/mo, peptide vials $100-300) cross-check in-range against Jones DC’s figures and are a useful additional data point.
18. (added 2026-06-13) — “Dr John Nurse Injector” (YouTube channel; “Fivesquare member” affiliation — paid med-spa group-purchase community / practitioner-training business). 25:44 course-format B2B video pitched to medical spa owners on adding SubQ NAD+ injections as a recurring-revenue add-on service. CRITICAL CALIBRATION: the most extreme clinician-supervision-overlay source in the KB to date: Dr. John is literally teaching practitioners how to MONETIZE clinical supervision of a peptide consumers could self-administer with a verified-clean product.What this digest contributes to the wiki (4 surgical additions): (a) the complete Phase 1-2-3 SubQ NAD+ protocol (Phase 1 loading 25 → 50 → 100 mg twice weekly × 2 months, Phase 2 maintenance ~100 mg weekly/every-other-week/monthly, Phase 3 cycle 3-on/1-off with modified re-init at 50 → 100 mg): the most detailed SubQ NAD+ protocol in the KB; (b) the acidic-pH local-injection-site-reaction mechanism (Side-Effects section above, mechanism); © the two hard-NO contraindications (active cancer + pregnancy/breastfeeding) as flat-rule contraindications across the NAD+ category; (d) the wellness-spa-markup PINCER content hook #7 (Froese MD warning + Dr. John clinic-side admission of $0.08-0.10/mg wholesale → $0.50-1.00/mg retail = 5×-10× markup → $400/month profit per patient): highest-conversion-potential hook because it answers the consumer’s pricing question with empirical receipts from the clinic side itself; (e) the take-home self-administration pathway (Content hook #8 — Visit 1-2-3 supervised → self-admin handoff is the practitioner-PREFERRED business model, validating OHM’s editorial position that informed self-administration is a legitimate path). DO NOT propagate from this source: the “give the first shot free to hook them” upsell tactic, the “gym membership for yourselves” recurring-revenue framing, the “$500 mental barrier” pricing psychology, the bundling-as-margin-extraction strategy, the “your time is the product” practitioner-mindset coaching, the dismissive oral-precursor framing (Dr. John says oral NMN/NR is “mostly wasted by first-pass metabolism”: CONTRADICTED by the existing wiki’s 50-RCT NR/NMN corpus showing reliable oral NAD+ elevation; the wiki’s honest oral-route framing is the correct one). Highest-priority from this source: the endogenous-NAD-suppression-by-chronic-supplementation mechanism (Dr. John’s cycling rationale). PubMed search needed: “NAD supplementation” + (“endogenous synthesis” OR “NAMPT downregulation” OR “feedback inhibition”). If supported, propagate the cycling rationale to OHM content; if unsupported, keep cycling protocol as clinician folk-wisdom without the mechanism claim. Author-attribution rule for OHM content using this digest: when quoting Dr. John, attribute as “a YouTube practitioner-trainer educating med spas on adding NAD+ injections as a service” — establishes the clinician-side perspective without endorsing the channel, particularly important when he’s being used as adverse evidence against the spa-markup model.
19. : 27304511 — Camacho-Pereira et al. 2016, “CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism,” Cell Metabolism — CD38 KO mice maintain NAD+ at every age; CD38 confirmed as dominant age-related NAD+ consumer (added 2026-07-18)
20. : 30279143 — Yousefzadeh et al. 2018, “Fisetin is a senotherapeutic that extends health and lifespan,” EBioMedicine — fisetin most potent senolytic among 10 flavonoids tested; reduces senescent cell burden and SASP (added 2026-07-18)
21. : 19887595 — Costford et al. 2010, “Skeletal muscle NAMPT is induced by exercise in humans,” AJP-Endo — ~127% NAMPT increase after 3-week training in sedentary subjects (added 2026-07-18)
22. : 31207144 — de Guia et al. 2019, “Aerobic and resistance exercise training reverses age-dependent decline in NAD+ salvage capacity in human skeletal muscle,” Physiological Reports — NAMPT increase 12-30% across aerobic + resistance in young and older cohorts (added 2026-07-18)
23. (added 2026-07-18) — Josh Holyfield (YouTube Shorts, 2:38, video ID uyQ3BG-ate8). “NAD+ Supplements Are a Waste of Money (Here’s What Actually Works).” Contribution: “drain problem” consumer framing (senescent cells → CD38, damaged mitochondria → PARPs); prompted addition of PMID 27304511, 30279143, 19887595, 31207144 + exercise/NAMPT section + fisetin adjunct note + SS-31/PARP drain cross-link. All claims in that section verified against primary lit before entry.